Compare BHB & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHB | ANNX |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 675.0M | 726.1M |
| IPO Year | 1995 | 2020 |
| Metric | BHB | ANNX |
|---|---|---|
| Price | $40.61 | $3.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $41.00 | $15.43 |
| AVG Volume (30 Days) | 83.4K | ★ 3.4M |
| Earning Date | 10-22-2026 | 11-09-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $13.09 | N/A |
| Revenue Next Year | $4.36 | N/A |
| P/E Ratio | $23.05 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.50 | $2.54 |
| 52 Week High | $41.12 | $7.18 |
| Indicator | BHB | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 42.75 |
| Support Level | $38.82 | $3.71 |
| Resistance Level | $41.07 | $4.37 |
| Average True Range (ATR) | 0.80 | 0.24 |
| MACD | 0.22 | 0.02 |
| Stochastic Oscillator | 94.21 | 43.65 |
Bar Harbor Bankshares Inc is a bank holding company along with its subsidiaries that offers a full range of financial services products, brokerage services through third-party brokerage arrangements, and also trust and investment management services to individuals, businesses, non-profit organizations, and municipalities. Its products and services consist of checking, deposits, cards, mobile banking, online services, loans, merchant services, trust, fiduciary services, investment planning, education funding, and individual retirement planning.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.